Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.

Journal of inherited metabolic disease - 1 Mar 2017

Osborn Mark J, Webber Beau R, McElmurry Ronald T, Rudser Kyle D, DeFeo Anthony P, Muradian Michael, Petryk Anna, Hallgrimsson Benedikt, Blazar Bruce R, Tolar Jakub, Braunlin Elizabeth A

Abstract excerpt

Mucopolysaccharidosis type I (MPS IH) is a lysosomal storage disease (LSD) caused by inactivating mutations to the alpha-L-iduronidase (IDUA) gene. Treatment focuses on IDUA enzyme replacement and currently employed methods can be non-uniform in their efficacy particularly for the cardiac and craniofacial pathology. Therefore, we undertook efforts to better define the pathological cascade accounting for treatment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiotensin Receptor Antagonists
Share to Craniofacial Abnormalities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Diseases

Share to Iduronidase

Share to Losartan

Share to Mucopolysaccharidosis I

Share to Receptors, Angiotensin

Share to Renin-Angiotensin System

Source

Open in PubMed Open full text

Identifiers

PMID: 27743312
DOI: 10.1007/s10545-016-9988-z
PMCID: PMC5335863

Genes

IDUA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.PMID 27743312Read ↗

Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.Semantic proximity Read ↗

Cardiac pathology in mucopolysaccharidosis I mice: Losartan modifies ERK1/2 activation during cardiac remodeling.Semantic proximity Read ↗

Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene.Semantic proximity Read ↗

Phenotypic characterisation of the Mucopolysaccharidosis Type I (MPSI) Idua-W392X mouse model reveals increased anxiety-related traits in female mice.Semantic proximity Read ↗

Identification of an α-l-iduronidase (IDUA) M1T mutation in a Chinese family with autosomal recessive mucopolysaccharidosis I.Semantic proximity Read ↗

Losartan shows limited benefit in preclinical models of Geleophysic dysplasiaSemantic proximity Read ↗

A novel mucopolysaccharidosis type II mouse model with an iduronate-2-sulfatase-P88L mutation.Semantic proximity Read ↗

Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In Vivo Genome Editing.Semantic proximity Read ↗

A commentary on 10 years of aldose reductase inhibition for limited joint mobility in diabetes.Semantic proximity Read ↗

Murine MPS I: insights into the pathogenesis of Hurler syndromeSemantic proximity Read ↗

Sexual behaviour in a murine model of mucopolysaccharidosis type I (MPS I).Semantic proximity Read ↗

Col4a1 mutation in mice causes defects in vascular function and low blood pressure associated with reduced red blood cell volume.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.